CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells

Medical Oncology

Volumn 32, Issue 5, 2015, Pages

  Pervaiz, Asim ^a   Ansari, Shariq ^a   Berger, Martin R ^a   Adwan, Hassan ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b GERMAN UNIVERSITY IN CAIRO   (Egypt)

Author keywords

Apoptosis induction; Caspases activation; C C chemokine receptor type 5; Maraviroc; SW480; SW620

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 4; CASPASE 5; CASPASE 7; CASPASE 9; CHEMOKINE RECEPTOR CCR5; CYCLIN D1; CYCLIN E; FAS LIGAND; INTERLEUKIN 1BETA CONVERTING ENZYME; MARAVIROC; PROTEIN BCL 2; PUMA PROTEIN; ANTINEOPLASTIC AGENT; CCR5 PROTEIN, HUMAN; CYCLOHEXANE DERIVATIVE; MESSENGER RNA; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLOHEXANES; G1 PHASE; HUMANS; RECEPTORS, CCR5; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84926295202     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0607-x     Document Type: Article

References (45)

1. Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002;42:469–99. doi:10.1146/annurev.pharmtox.42.091901.115838.
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–7.
3. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today. 1999;20(6):254–7.
4. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42. doi:10.1146/annurev.immunol.18.1.217.
5. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007;25:787–820. doi:10.1146/annurev.immunol.24.021605.090529.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0.
7. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BJ. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404(6776):407–11. doi:10.1038/35006097.
8. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4(7):540–50. doi:10.1038/nrc1388.
9. Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res. 2011;317(5):575–89. doi:10.1016/j.yexcr.2011.01.005.
10. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21(1):27–39. doi:10.1016/j.cytogfr.2009.11.007.
11. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16(3):133–44. doi:10.1016/j.molmed.2010.01.003.
12. Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007;256(2):137–65. doi:10.1016/j.canlet.2007.05.013.
13. Richmond A. Chemokine modulation of the tumor microenvironment. Pigment Cell Melanoma Res. 2010;23(3):312–3. doi:10.1111/j.1755-148X.2010.00714.x.
14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.
15. Garborg K, Holme O, Loberg M, Kalager M, Adami HO, Bretthauer M. Current status of screening for colorectal cancer. Ann Oncol. 2013;24(8):1963–72. doi:10.1093/annonc/mdt157.
16. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35(11):3362–7. doi:10.1021/bi952950g.
17. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem. 1996;271(29):17161–6.
18. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004;16(11):1201–10. doi:10.1016/j.cellsig.2004.04.007.
19. New DC, Wong YH. CC chemokine receptor-coupled signalling pathways. Acta Biochimica et Biophysica Sinica. 2003;35(9):779–88.
20. Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Muller M, et al. Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int J Colorectal Dis. 2010;25(4):417–24. doi:10.1007/s00384-009-0868-y.
21. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, et al. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol. 2009;460:105–21. doi:10.1016/S0076-6879(09)05205-7.
22. Schimanski CC, Moehler M, Gockel I, Zimmermann T, Lang H, Galle PR, et al. Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. J Cancer Res Clin Oncol. 2011;137(7):1139–45. doi:10.1007/s00432-011-0980-6.
23. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 2014;352(1):36–53. doi:10.1016/j.canlet.2013.10.006.
24. de Oliveira CE, Oda JM, Losi Guembarovski R, de Oliveira KB, Ariza CB, Neto JS, et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014;2014:126954. doi:10.1155/2014/126954.
25. Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72(5):1092–102. doi:10.1158/0008-5472.CAN-11-2493.
26. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4(2):141–54. doi:10.1007/s12307-010-0052-5.
27. Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, et al. CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRbeta in colorectal carcinoma. PLoS ONE. 2011;6(12):e28842. doi:10.1371/journal.pone.0028842.
28. Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, et al. The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer. 2015;112(2):319–28. doi:10.1038/bjc.2014.572.
29. Yost R, Pasquale TR, Sahloff EG. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm. 2009;66(8):715–26. doi:10.2146/ajhp080206.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262.
31. Velasco-Velazquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72(15):3839–50. doi:10.1158/0008-5472.CAN-11-3917.
32. Ochoa-Callejero L, Perez-Martinez L, Rubio-Mediavilla S, Oteo JA, Martinez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS ONE. 2013;8(1):e53992. doi:10.1371/journal.pone.0053992.
33. Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D, et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013;6(6):784–93.
34. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008;65(Suppl 1):60–7. doi:10.1111/j.1365-2125.2008.03137.x.
35. Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, et al. Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev. 1999;13(22):3027–33.
36. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18(22):2699–711. doi:10.1101/gad.1256504.
37. Gudas JM, Payton M, Thukral S, Chen E, Bass M, Robinson MO, et al. Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers. Mol Cell Biol. 1999;19(1):612–22.
38. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516. doi:10.1080/01926230701320337.
39. Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 2013;20(1):64–76. doi:10.1038/cdd.2012.93.
40. Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, et al. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ. 2006;13(10):1619–30. doi:10.1038/sj.cdd.4402015.
41. Rautureau GJ, Day CL, Hinds MG. Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci. 2010;11(4):1808–24. doi:10.3390/ijms11041808.
42. Xu G, Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res. 2007;17(9):759–71. doi:10.1038/cr.2007.52.
43. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7(4):313–9.
44. Abraham MC, Shaham S. Death without caspases, caspases without death. Trends Cell Biol. 2004;14(4):184–93. doi:10.1016/j.tcb.2004.03.002.
45. Denes A, Lopez-Castejon G, Brough D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis. 2012;3:e338. doi:10.1038/cddis.2012.86.